Calyxt, Inc. (CLXT)
(Delayed Data from NSDQ)
$15.70 USD
+0.19 (1.23%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.67 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.70 USD
+0.19 (1.23%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.67 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Calyxt (CLXT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of 7.41% and 96.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Archer Daniels' (ADM) Stock Up on Q2 Earnings & Sales Beat
by Zacks Equity Research
Archer Daniels' (ADM) better-than-expected second-quarter results can be attributed to the company's strategic growth initiatives and robust cost-saving efforts.
US-EU Talks: A Boon for Agriculture and Energy Stocks
by Zacks Equity Research
If both countries follow their agendas, domestic agriculture and energy sectors should benefit.
Zacks Industry Outlook Highlights: Archer Daniels Midland, Calyxt and Adecoagro
by Zacks Equity Research
Zacks Industry Outlook Highlights: Archer Daniels Midland, Calyxt and Adecoagro
Calyxt Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Calyxt Sees Hammer Chart Pattern: Time to Buy?
Agriculture Operations Outlook: High Food Demand Drives Resilience
by Zacks Equity Research
Increased demand for food due to rise in global population and the changing dietary preferences makes agri-business resilient. Global food demand is expected to rise by 70% by 2050.
Will Segment Sales Growth Drive PepsiCo's (PEP) Q2 Earnings?
by Zacks Equity Research
PepsiCo's (PEP) efforts to improve performance through product launches, fortify emerging market presence, aggressive marketing, productivity improvement and cost-saving initiatives are impressive.
Archer Daniels Hits 52-Week High on Robust Growth Strategies
by Zacks Equity Research
Archer Daniels (ADM) gains from its strategic initiatives such as business portfolio management, cost-savings plan and Readiness program.
The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt
5 Best Performing IPOs of 2017
by Zacks Equity Research
The year 2017 marked a bounce back for the U.S. IPO market thanks to improving economy and consumer sentiment. Successful IPOs poured in primarily from the biotech and tech sectors.
Archer Daniels' Cost Savings on Track, Soft Sales a Concern
by Zacks Equity Research
Archer-Daniels-Midland (ADM) focuses on strengthening its business through increased cost savings. However, its top line has been lagging the estimates for over three years now.